New diabetes clinical trial: Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
Published on: 2026-04-06T04:00:00Z
Conditions: Obesity; Weight Reduction; Cardiometabolic Risk Factors
Interventions: Drug: Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
Sponsors: Asian Institute Of Medical Sciences
Recruiting
https://ift.tt/lexSIRM
Conditions: Obesity; Weight Reduction; Cardiometabolic Risk Factors
Interventions: Drug: Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
Sponsors: Asian Institute Of Medical Sciences
Recruiting
https://ift.tt/lexSIRM
Comments
Post a Comment